Subjective Vertical Position Allows Prediction of Postural Deterioration in Patients with Parkinson’s Disease

Table 2

Baseline characteristics of patients who underwent 1 year of follow-up and those who did not.

	Patients who were followed up for 1 year ()	Patients who were not followed up for 1 year ()	value
Age (years)	70.3 ± 6.7	73.2 ± 11.6	0.35
Sex (male/female)	9/9	8/13	0.45
Disease duration (years)	8.6 ± 6.6	6.0 ± 3.5	0.28
MMSE	28.3 ± 1.7	27.3 ± 2.2	0.22
mH&Y	2.5 ± 0.6	2.6 ± 0.8	0.90
FFT angle (°)	12.8 ± 12.9	8.0 ± 15.0	0.23
SV angle (°)	6.0 ± 9.8	4.5 ± 9.9	0.77
UPDRS I	2.2 ± 1.6	2.0 ± 1.2	0.92
UPDRS II	8.6 ± 6.0	7.3 ± 5.2	0.64
UPDRS III	14.2 ± 9.4	16.2 ± 8.9	0.50
UPDRS IV	2.4 ± 2.8	2.4 ± 2.2	0.69
UPDRS total	27.3 ± 13.7	28.0 ± 13.9	0.88
LED (mg/day)	636 ± 199.4	749.0 ± 349.5	0.25

MMSE, Mini-Mental State Examination; mH&Y, modified Hoehn & Yahr Scale; FFT, forward flexion of trunk; SV, subjective vertical position; UPDRS, Unified Parkinson’s Disease Rating Scale; LED, levodopa-equivalent dose.